[P53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer: a meta-analysis].
OBJECTIVE
To explore the relation between p53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer (NSCLC).


METHODS
The DerSimonian-Laird random effect model was used to analyze the data reported in relevant literature.


RESULTS
Sixteen trials involving 1070 patients were retrieved. The overall positivity rate of p53 was 50.4% and overall response rate to cisplatin was 38.7%. The test for heterogeneity showed that all eligible studies had heterogeneity (chi 2-/+47.57, P<0.0001). The combined odds ratio (OR) was 1.37, with 95% confidence interval of 0.84-2.24.


CONCLUSIONS
Expression of p53 protein in patients with NSCLC is not associated with the chemosensitivity to cisplatin.
Wang
Jin-liang
JL
Department of Medical Oncology, General Hospital of PLA, Beijing 100853, China. wangjl301@yahoo.com.cn
Jiao
Shun-chang
SC
Ye
Ping
P
Li
Jin-yu
JY
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D002945:Cisplatin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis*
D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53; D002945:Cisplatin